Literature DB >> 27578609

Outer membrane vesicles derived from Salmonella Typhimurium mutants with truncated LPS induce cross-protective immune responses against infection of Salmonella enterica serovars in the mouse model.

Qiong Liu1, Qing Liu2, Jie Yi2, Kang Liang2, Tian Liu2, Kenneth L Roland3, Yanlong Jiang4, Qingke Kong5.   

Abstract

Salmonella enterica cause diarrheal and systemic diseases and are of considerable concern worldwide. Vaccines that are cross-protective against multiple serovars could provide effective control of Salmonella-mediated diseases. Bacteria-derived outer membrane vesicles (OMVs) are highly immunogenic and are capable of eliciting protective immune responses. Alterations in lipopolysaccharide (LPS) length can result in outer membrane remodeling and composition of outer membrane proteins (OMPs) changing. In this study, we investigated the impact of truncated LPS on both the production and immunogenicity of Salmonella OMVs, including the ability of OMVs to elicit cross-protection against challenge by heterologous Salmonella strains. We found that mutations in waaJ and rfbP enhanced vesiculation, while mutations in waaC, waaF and waaG inhibited this process. Animal experiments indicated that OMVs from waaC, rfaH and rfbP mutants induced stronger serum immune responses compared to OMVs from the parent strain, while all elicited protective responses against the wild-type S. Typhimurium challenge. Furthermore, intranasal or intraperitoneal immunization with OMVs derived from the waaC and rfbP mutants elicited significantly higher cross-reactive IgG responses and provided enhanced cross-protection against S. Choleraesuis and S. Enteritidis challenge than the wild-type OMVs. These results indicate that truncated-LPS OMVs are capable of conferring cross protection against multiple serotypes of Salmonella infection. Copyright Â
© 2016 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Cross-protection; Lipopolysaccharide (LPS); Mouse model; Outer membrane vesicles (OMVs); Truncated LPS

Mesh:

Substances:

Year:  2016        PMID: 27578609      PMCID: PMC5206754          DOI: 10.1016/j.ijmm.2016.08.004

Source DB:  PubMed          Journal:  Int J Med Microbiol        ISSN: 1438-4221            Impact factor:   3.473


  59 in total

Review 1.  Structures of gram-negative cell walls and their derived membrane vesicles.

Authors:  T J Beveridge
Journal:  J Bacteriol       Date:  1999-08       Impact factor: 3.490

2.  STUDIES ON THE GRAM-NEGATIVE CELL WALL. I. EVIDENCE FOR THE ROLE OF 2-KETO- 3-DEOXYOCTONATE IN THE LIPOPOLYSACCHARIDE OF SALMONELLA TYPHIMURIUM.

Authors:  M J OSBORN
Journal:  Proc Natl Acad Sci U S A       Date:  1963-09       Impact factor: 11.205

Review 3.  Bacterial outer membrane vesicles and the host-pathogen interaction.

Authors:  Meta J Kuehn; Nicole C Kesty
Journal:  Genes Dev       Date:  2005-11-15       Impact factor: 11.361

4.  Outer membrane vesicles as an acellular vaccine against Acinetobacter baumannii.

Authors:  Michael J McConnell; Carlos Rumbo; Germán Bou; Jerónimo Pachón
Journal:  Vaccine       Date:  2011-06-14       Impact factor: 3.641

5.  A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis.

Authors:  Wildaliz Nieves; Hailey Petersen; Barbara M Judy; Carla A Blumentritt; Kasi Russell-Lodrigue; Chad J Roy; Alfredo G Torres; Lisa A Morici
Journal:  Clin Vaccine Immunol       Date:  2014-03-26

6.  The global burden of nontyphoidal Salmonella gastroenteritis.

Authors:  Shannon E Majowicz; Jennie Musto; Elaine Scallan; Frederick J Angulo; Martyn Kirk; Sarah J O'Brien; Timothy F Jones; Aamir Fazil; Robert M Hoekstra
Journal:  Clin Infect Dis       Date:  2010-03-15       Impact factor: 9.079

7.  Mucosally delivered Salmonella live vector vaccines elicit potent immune responses against a foreign antigen in neonatal mice born to naive and immune mothers.

Authors:  Alejandra V E Capozzo; Lilian Cuberos; Myron M Levine; Marcela F Pasetti
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

8.  Cross-reactivity of rabbit antibodies to lipopolysaccharides of Escherichia coli J5 and other gram-negative bacteria.

Authors:  G R Siber; S A Kania; H S Warren
Journal:  J Infect Dis       Date:  1985-11       Impact factor: 5.226

Review 9.  A review of vaccine research and development: human enteric infections.

Authors:  Marc P Girard; Duncan Steele; Claire-Lise Chaignat; Marie Paule Kieny
Journal:  Vaccine       Date:  2005-10-21       Impact factor: 3.641

10.  Soluble flagellin coimmunization attenuates Th1 priming to Salmonella and clearance by modulating dendritic cell activation and cytokine production.

Authors:  Adriana Flores-Langarica; Saeeda Bobat; Jennifer L Marshall; Juan Carlos Yam-Puc; Charlotte N Cook; Karine Serre; Robert A Kingsley; Leopoldo Flores-Romo; Satoshi Uematsu; Shizuo Akira; Ian R Henderson; Kai M Toellner; Adam F Cunningham
Journal:  Eur J Immunol       Date:  2015-06-24       Impact factor: 5.532

View more
  16 in total

Review 1.  Vaccination against Salmonella Infection: the Mucosal Way.

Authors:  Rémi Gayet; Gilles Bioley; Nicolas Rochereau; Stéphane Paul; Blaise Corthésy
Journal:  Microbiol Mol Biol Rev       Date:  2017-06-14       Impact factor: 11.056

2.  Two Novel Salmonella Bivalent Vaccines Confer Dual Protection against Two Salmonella Serovars in Mice.

Authors:  Xinxin Zhao; Qinlong Dai; Renyong Jia; Dekang Zhu; Mafeng Liu; Mingshu Wang; Shun Chen; Kunfeng Sun; Qiao Yang; Ying Wu; Anchun Cheng
Journal:  Front Cell Infect Microbiol       Date:  2017-09-04       Impact factor: 5.293

3.  O-Serotype Conversion in Salmonella Typhimurium Induces Protective Immune Responses against Invasive Non-Typhoidal Salmonella Infections.

Authors:  Pei Li; Qing Liu; Hongyan Luo; Kang Liang; Jie Yi; Ying Luo; Yunlong Hu; Yue Han; Qingke Kong
Journal:  Front Immunol       Date:  2017-12-04       Impact factor: 7.561

4.  Overview of the Nontyphoidal and Paratyphoidal Salmonella Vaccine Pipeline: Current Status and Future Prospects.

Authors:  Scott M Baliban; Ying-Jie Lu; Richard Malley
Journal:  Clin Infect Dis       Date:  2020-07-29       Impact factor: 9.079

5.  PGE2 Augments Inflammasome Activation and M1 Polarization in Macrophages Infected With Salmonella Typhimurium and Yersinia enterocolitica.

Authors:  Austin E F Sheppe; Evangel Kummari; Alyssa Walker; Angela Richards; Winnie W Hui; Jung Hwa Lee; Lauren Mangum; Abdolsamad Borazjani; Matthew K Ross; Mariola J Edelmann
Journal:  Front Microbiol       Date:  2018-10-31       Impact factor: 5.640

Review 6.  Isolation and Functions of Extracellular Vesicles Derived from Parasites: The Promise of a New Era in Immunotherapy, Vaccination, and Diagnosis.

Authors:  Mojdeh Khosravi; Elnaz Sadat Mirsamadi; Hamed Mirjalali; Mohammad Reza Zali
Journal:  Int J Nanomedicine       Date:  2020-04-28

7.  Exploiting bacterial outer membrane vesicles as a cross-protective vaccine candidate against avian pathogenic Escherichia coli (APEC).

Authors:  Rujiu Hu; Jing Li; Yuezhen Zhao; Hua Lin; Liu Liang; Mimi Wang; Haojing Liu; Yuna Min; Yupeng Gao; Mingming Yang
Journal:  Microb Cell Fact       Date:  2020-06-03       Impact factor: 5.328

8.  Outer Membrane Vesicles Derived from Salmonella enterica Serotype Typhimurium Can Deliver Shigella flexneri 2a O-Polysaccharide Antigen To Prevent Shigella flexneri 2a Infection in Mice.

Authors:  Huizhen Tian; Biaoxian Li; Tian Xu; Haolin Yu; Jingxuan Chen; Haiyan Yu; Shan Li; Lingbing Zeng; Xiaotian Huang; Qiong Liu
Journal:  Appl Environ Microbiol       Date:  2021-09-10       Impact factor: 4.792

9.  An Outer Membrane Vesicle-Adjuvanted Oral Vaccine Protects Against Lethal, Oral Salmonella Infection.

Authors:  Jaikin E Harrell; Jonathan R Kurtz; David L Bauer; J Timothy Prior; Patrick S Gellings; Lisa A Morici; James B McLachlan
Journal:  Pathogens       Date:  2021-05-18

10.  Pathogenic signature of invasive non-typhoidal Salmonella in Africa: implications for vaccine development.

Authors:  Giulia Piccini; Emanuele Montomoli
Journal:  Hum Vaccin Immunother       Date:  2020-07-21       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.